Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304909 | 0.82 | FDPS (0.38) | FDPSTSHRCYP3A4LMNAPOLB | |
| SCHEMBL28667189 | 0.79 | LMNA (0.37) | FDPSTSHRLMNAPOLBGAA | |
| SCHEMBL3294905 | 0.79 | CYP3A4 (0.38) | FDPSTSHRCYP3A4LMNAPOLB | |
| SCHEMBL29268091 | 0.78 | AR (0.37) | FDPSTSHRCYP3A4LMNAPOLB | |
| SCHEMBL13315230 | 0.75 | CYP3A4 (0.36) | FDPSTSHRCYP3A4LMNAPOLB | |
| SCHEMBL309198 | 0.73 | FDPS (0.38) | FDPSTSHRCYP3A4GAAMAPT | |
| SCHEMBL14451165 | 0.73 | FDPS (0.38) | FDPSTSHRCYP3A4GAAMAPT | |
| SCHEMBL28257309 | 0.70 | FDPS (0.31) | FDPSCYP3A4 | |
| SCHEMBL31211936 | 0.70 | FDPS (0.36) | FDPSTSHRCYP3A4GAAMAPT | |
| SCHEMBL19992033 | 0.70 | LMNA (0.38) | FDPSTSHRLMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646410-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB Science (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024146923-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB SCIENCE (FR) | 2024-07-11 | — | — | WO | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | FDPS 121/4885TSHR 2299/4885CYP3A4 201/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | FDPS 121/4885TSHR 2299/4885CYP3A4 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.